Who are Clopixol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): XANOMELINE, Azilect, Abilify, Clarinex, Fareston, Risperdal.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zuclopenthixol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Clopixol — Competitive Intelligence Brief

Clopixol (ZUCLOPENTHIXOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: High Risk QT Prolonging Agents. Area: Neuroscience.

discontinued High Risk QT Prolonging Agents 5-hydroxytryptamine receptor 6 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Clopixol (ZUCLOPENTHIXOL). Clopixol works by blocking the 5-hydroxytryptamine receptor 6, which helps to regulate mood and reduce symptoms of schizophrenia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopixol TARGET	ZUCLOPENTHIXOL		discontinued	High Risk QT Prolonging Agents	5-hydroxytryptamine receptor 6
XANOMELINE	XANOMELINE		marketed		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A	2024-01-01
Azilect	RASAGILINE	Teva	marketed	Monoamine Oxidase Inhibitor	5-hydroxytryptamine receptor 6	2006-01-01
Abilify	aripiprazole	Generic (originally Otsuka/BMS)	marketed	Third-generation antipsychotic (D2 partial agonist)	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	2002-11-15
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	marketed	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Fareston	TOREMIFENE	Kyowa Kirin	marketed	Estrogen Agonist/Antagonist	5-hydroxytryptamine receptor 6	1997-01-01
Risperdal	risperidone	Johnson & Johnson (Janssen)	marketed	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	1993-12-29

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-26 — Risperdal · 10406160 · Formulation · US
2026-07-28 — Abilify · 9125939 · Method of Use · US
2026-09-14 — Abilify · 7978064 · Formulation · US
2026-09-26 — Risperdal · 9597402 · Formulation · US
2026-09-26 — Risperdal · 10058554 · Method of Use · US
2026-11-05 — Risperdal · 11110093 · Formulation · US
2027-03-02 — Abilify · 8759350 · Method of Use · US
2027-11-12 — Risperdal · 8741327 · Formulation · US
2027-11-12 — Risperdal · 8221778 · Formulation · US
2027-11-19 — Abilify · 9444503 · Formulation · US
2028-02-13 — Risperdal · 11712475 · Method of Use · US
2028-02-13 — Risperdal · 10010612 · Formulation · US
2028-02-13 — Risperdal · 9180197 · Formulation · US
2028-02-13 — Risperdal · 11013809 · Formulation · US
2028-02-13 — Risperdal · 10376590 · Method of Use · US
2028-02-13 — Risperdal · 9186413 · Method of Use · US
2028-12-16 — Abilify · 9119554 · Formulation · US
2029-03-05 — Abilify · 9258035 · Formulation · US
2029-03-05 — Abilify · 9060708 · Formulation · US
2029-04-09 — Abilify · 8674825 · Formulation · US
2029-07-06 — Abilify · 8956288 · Formulation · US
2029-07-26 — Abilify · 10441194 · Formulation · US
2029-08-19 — Abilify · 8945005 · Formulation · US
2029-09-15 — Abilify · 9433371 · Formulation · US
2029-12-05 — Abilify · 8718193 · Formulation · US
2029-12-15 — Abilify · 9149577 · Formulation · US
2030-03-29 — Abilify · 8847766 · Formulation · US
2030-04-27 — Abilify · 8545402 · Formulation · US
2030-06-21 — Abilify · 8114021 · Formulation · US
2030-09-15 — Abilify · 11464423 · Formulation · US

Sponsor landscape (High Risk QT Prolonging Agents class)

· 8 drugs in this class
Cephalon · 1 drug in this class
Pfizer · 1 drug in this class
Roxane · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopixol — Competitive Intelligence Brief. https://druglandscape.com/ci/zuclopenthixol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab